No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase

被引:81
作者
Hoda, F
Nicholl, D
Bennett, P
Arranz, M
Aitchison, KJ
AlChalabi, A
Kunugi, H
Vallada, H
Leigh, PN
Chaudhuri, KR
Collier, DA
机构
[1] QUEEN ELIZABETH HOSP, DEPT NEUROL, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND
[2] INST PSYCHIAT, MOL GENET SECT, LONDON SE5 8AF, ENGLAND
[3] INST PSYCHIAT, DEPT NEUROPATHOL, LONDON SE5 8AF, ENGLAND
[4] INST PSYCHIAT, DEPT NEUROL, LONDON SE5 8AF, ENGLAND
关键词
D O I
10.1006/bbrc.1996.1731
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Idiopathic Parkinson's disease (IPD) is characterised by the loss of pigmented neurones in the substantia nigra leading to reduced tyrosine hydroxylase activity and depletion of dopamine. Treatments attempt to correct this deficit by the use of levodopa and inhibitors of dopamine metabolising enzymes such as catechol-O-methytransferase (COMT). A common amino-acid polymorphism in COMT, valine-108-methionine, results in a low activity form of the enzyme which we hypothesised may influence susceptibility to IPD. We examined this polymorphism in 139 Caucasian subjects viith IPD and 173 control subjects, using a PCR-RFLP and a novel Amplification Refractory Mutation System (ARMS) assay. Allele and genotype frequencies were similar in the affected and control subjects, indicating that variation of COMT activity is not an aetiological factor in IPD. We have also characterised a new polymorphism, 256C/G, which is not associated with IPD. However it remains possible that allelic variation in COMT influences severity, type of pathology or treatment response to levodopa or COMT inhibitors. (C) 1996 Academic Press, Inc.
引用
收藏
页码:780 / 784
页数:5
相关论文
共 30 条
  • [21] OU J, 1985, GENET EPIDEMIOL, V2, P79
  • [22] RAPID HLA TYPING BY MULTIPLEX AMPLIFICATION REFRACTORY MUTATION SYSTEM
    PATEL, P
    LO, YMD
    BELL, JI
    WAINSCOAT, JS
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1993, 46 (12) : 1105 - 1108
  • [23] TYROSINE-HYDROXYLASE POLYMORPHISM IN FAMILIAL AND SPORADIC PARKINSONS-DISEASE
    PLANTEBORDENEUVE, V
    DAVIS, MB
    MARAGANORE, DM
    MARSDEN, CD
    HARDING, AE
    [J]. MOVEMENT DISORDERS, 1994, 9 (03) : 337 - 339
  • [24] REILLY DK, 1993, ADV NEUROL, V37, P51
  • [25] DIFFERENCE IN ERYTHROCYTE CATECHOL-O-METHYLTRANSFERASE ACTIVITY BETWEEN ORIENTALS AND CAUCASIANS - DIFFERENCE IN LEVODOPA TOLERANCE
    RIVERACALIMLIM, L
    REILLY, DK
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) : 804 - 809
  • [26] ANATOMIC AND DISEASE SPECIFICITY OF NADH COQ1 REDUCTASE (COMPLEX-I) DEFICIENCY IN PARKINSONS-DISEASE
    SCHAPIRA, AHV
    MANN, VM
    COOPER, JM
    DEXTER, D
    DANIEL, SE
    JENNER, P
    CLARK, JB
    MARSDEN, CD
    [J]. JOURNAL OF NEUROCHEMISTRY, 1990, 55 (06) : 2142 - 2145
  • [27] SMITH, 1992, LANCET, V340, P64
  • [28] SYKES BC, 1983, LANCET, V2, P787
  • [29] GENOMIC ORGANIZATION OF THE HUMAN CATECHOL O-METHYLTRANSFERASE GENE AND ITS EXPRESSION FROM 2 DISTINCT PROMOTERS
    TENHUNEN, J
    SALMINEN, M
    LUNDSTROM, K
    KIVILUOTO, T
    SAVOLAINEN, R
    ULMANEN, I
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 223 (03): : 1049 - 1059
  • [30] TREVOR AJ, 1987, J NEURAL TRANSM, P73